



## MARKET ANNOUNCEMENT

# Uscom end of financial year update: Revenue up, costs down.

Thursday, 24 July 2008: Uscom (ASX Code: UCM) today provided an update to shareholders including unaudited 2008 Financial Year results.

Sales revenue in 2008 was \$960k, a 10% increase over the previous year. Sales revenue would have been in excess of \$1M but for the weak US dollar, as 50% of revenues were received in US\$. Importantly Uscom has reduced cash consumption by 30% compared to 2007 to less than \$1.9M, leaving a cash balance of \$2.5M. The year also saw the USCOM 1A installed base exceed 150 units worldwide, providing critical mass in our targeted markets.

Uscom CEO, Mr Paul Butler, said "We had solid growth in all our target markets, our operating costs are down 30%, and we have identified paths forward and are well advanced in marketing partnership discussions to accelerate US market access."

Mr Rob Phillips, Executive Chairman and Director of Clinical Science said "A principle goal in founding USCOM was to establish a new standard of care in medical monitoring. This year saw the publication of a number of studies moving us further toward this goal in pediatrics, Emergency Departments, Intensive Care Units and anaesthesia. This evidence is now driving practice leading centres to adopt the USCOM technology. The published evidence and increased adoption advances our claims for reimbursement and confirms that USCOM is saving lives worldwide. Uscom is achieving it's milestones on the path to creating an important global haemodynamics company."

### About Uscom

Uscom Limited is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a device for the safe and accurate measurement of cardiac output, a non-invasive alternative to the current invasive methods. Uscom offers a completely safe, painless and quick method of accurately measuring how well the heart is pumping. With its real-time beat-to-beat information across multiple parameters of cardiac function and advanced serial measurement capabilities, clinicians can accurately quantify the impact of therapy. The device is ideally suited to the Emergency Care setting where it is critical to monitor changes in cardiac output as fluids are applied.

The Company has secured regulatory approval for sale of the Uscom Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).

### **Uscom Contacts**

Paul Butler  
Chief Executive Officer  
Office: 02 9247 4144  
[paul.butler@uscom.com.au](mailto:paul.butler@uscom.com.au)

Rob Phillips  
Executive Chairman  
Office: 02 9247 4144  
[rob@uscom.com.au](mailto:rob@uscom.com.au)